PL3750913T3 - Epitop igg i jego zastosowanie jako cel - Google Patents
Epitop igg i jego zastosowanie jako celInfo
- Publication number
- PL3750913T3 PL3750913T3 PL18904885.3T PL18904885T PL3750913T3 PL 3750913 T3 PL3750913 T3 PL 3750913T3 PL 18904885 T PL18904885 T PL 18904885T PL 3750913 T3 PL3750913 T3 PL 3750913T3
- Authority
- PL
- Poland
- Prior art keywords
- target
- application
- igg epitope
- epitope
- igg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91091—Glycosyltransferases (2.4)
- G01N2333/91148—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810146884 | 2018-02-12 | ||
| CN201810330585.1A CN108610414B (zh) | 2018-02-12 | 2018-04-13 | IgG抗原表位及其作为靶点的应用 |
| PCT/CN2018/099279 WO2019153674A1 (zh) | 2018-02-12 | 2018-08-08 | IgG抗原表位及其作为靶点的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3750913T3 true PL3750913T3 (pl) | 2024-03-04 |
Family
ID=63659963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18904885.3T PL3750913T3 (pl) | 2018-02-12 | 2018-08-08 | Epitop igg i jego zastosowanie jako cel |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12077602B2 (pl) |
| EP (1) | EP3750913B1 (pl) |
| JP (1) | JP7156647B2 (pl) |
| CN (1) | CN108610414B (pl) |
| ES (1) | ES2965624T3 (pl) |
| HR (1) | HRP20231636T1 (pl) |
| HU (1) | HUE064723T2 (pl) |
| PL (1) | PL3750913T3 (pl) |
| RS (1) | RS64968B1 (pl) |
| SM (1) | SMT202300459T1 (pl) |
| WO (1) | WO2019153674A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108610414B (zh) | 2018-02-12 | 2022-09-13 | 北京大学 | IgG抗原表位及其作为靶点的应用 |
| CN109529051A (zh) * | 2018-12-10 | 2019-03-29 | 大连医科大学 | 唾液酰基转移酶重组质粒及其与培美曲塞在制备抑制膀胱癌的增殖和侵袭药物中的应用 |
| CN114354927B (zh) * | 2021-03-18 | 2025-04-22 | 中国人民解放军陆军特色医学中心 | 唾液酸转移酶st3gal4作为egfr-tki耐药标志物的新应用 |
| CN114409790B (zh) * | 2022-03-31 | 2022-09-13 | 北京大学 | 一种提高抗体药物效力的方法及抗体药物 |
| CN114920830B (zh) * | 2022-05-07 | 2023-05-16 | 北京大学 | Vκ4-1-IgLC多肽及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102901817A (zh) * | 2011-07-27 | 2013-01-30 | 北京大学 | Non-B Ig单抗RP215在细胞增殖、迁移及干细胞研究中的应用 |
| US8974786B2 (en) * | 2012-06-13 | 2015-03-10 | Vancouver Biotech Ltd. | Humanized antibodies to CA215 |
| CN105353132B (zh) * | 2015-11-13 | 2018-04-10 | 北京大学 | non B‑s IgG作为干/祖细胞标志物的应用 |
| CN108610414B (zh) * | 2018-02-12 | 2022-09-13 | 北京大学 | IgG抗原表位及其作为靶点的应用 |
-
2018
- 2018-04-13 CN CN201810330585.1A patent/CN108610414B/zh active Active
- 2018-08-08 US US16/969,189 patent/US12077602B2/en active Active
- 2018-08-08 ES ES18904885T patent/ES2965624T3/es active Active
- 2018-08-08 HR HRP20231636TT patent/HRP20231636T1/hr unknown
- 2018-08-08 EP EP18904885.3A patent/EP3750913B1/en active Active
- 2018-08-08 PL PL18904885.3T patent/PL3750913T3/pl unknown
- 2018-08-08 WO PCT/CN2018/099279 patent/WO2019153674A1/zh not_active Ceased
- 2018-08-08 RS RS20231186A patent/RS64968B1/sr unknown
- 2018-08-08 HU HUE18904885A patent/HUE064723T2/hu unknown
- 2018-08-08 SM SM20230459T patent/SMT202300459T1/it unknown
- 2018-08-08 JP JP2020564988A patent/JP7156647B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HUE064723T2 (hu) | 2024-04-28 |
| CN108610414B (zh) | 2022-09-13 |
| EP3750913C0 (en) | 2023-09-13 |
| US20200369785A1 (en) | 2020-11-26 |
| RS64968B1 (sr) | 2024-01-31 |
| EP3750913A1 (en) | 2020-12-16 |
| CN108610414A (zh) | 2018-10-02 |
| US12077602B2 (en) | 2024-09-03 |
| HRP20231636T1 (hr) | 2024-04-26 |
| ES2965624T3 (es) | 2024-04-16 |
| SMT202300459T1 (it) | 2024-01-10 |
| JP2021528376A (ja) | 2021-10-21 |
| EP3750913B1 (en) | 2023-09-13 |
| WO2019153674A1 (zh) | 2019-08-15 |
| JP7156647B2 (ja) | 2022-10-19 |
| EP3750913A4 (en) | 2021-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282968A (en) | Anti-NKG2A antibodies and their use | |
| IL276950A (en) | Anti-CD73 antibodies and uses thereof | |
| SG11202105885WA (en) | Anti-claudin antibodies and uses thereof | |
| IL279455A (en) | ANTI-PD-1 antibodies and their uses | |
| ZA202105676B (en) | Anti-trem2 antibodies and related methods | |
| SG11202104240TA (en) | Cll1-targeting antibody and application thereof | |
| IL275826A (en) | Anti-mct1 antibodies and their uses | |
| SG11202100888WA (en) | Anti-avb8 antibodies and compositions and uses thereof | |
| SG11202009874QA (en) | Antibody formulation | |
| IL280321A (en) | Antibodies against CXCR2 and their uses | |
| SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
| IL276675A (en) | Anti-PD-1 antibodies and uses thereof | |
| IL281202A (en) | Anti-TNFRSF9 antibodies and uses thereof | |
| ZA202100714B (en) | Anti-npr1 antibodies and uses thereof | |
| SG11202103064YA (en) | Antibody formulation | |
| IL277075A (en) | Anti-PHF-tau antibodies and uses thereof | |
| SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
| IL283180A (en) | Anti-PD-1 antibodies and their uses | |
| HUE064723T2 (hu) | IgG-epitóp és alkalmazása célpontként | |
| SG11202105161YA (en) | Anti-il-27 antibodies and uses thereof | |
| IL277330A (en) | Anti-IL-27 antibodies and uses thereof | |
| IL276548A (en) | Binding antibodies - BCMA and their uses | |
| SG11202012680TA (en) | Anti-l1cam antibodies and uses thereof | |
| ZA202004784B (en) | Humanized and de-immunized antibodies | |
| IL283926B1 (en) | Antibodies against alpha-synuclein and their uses |